Apogee Therapeutics (APGE) Shares Outstanding (2022 - 2026)

Apogee Therapeutics (APGE) has reported Shares Outstanding (Entity) for 5 consecutive years, with $75.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 26.54% year-over-year to $75.3 million; the TTM figure through Mar 2026 stood at $75.3 million (up 26.54% YoY), while the FY2025 annual figure was $69.0 million, up 16.07% from the prior year.
• Shares Outstanding (Entity) rose to $75.3 million in Q1 2026 per APGE's latest filing, from $69.0 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $75.3 million in Q1 2026 and bottomed at $1.2 million in Q2 2022.
• Historically, Shares Outstanding (Entity) has averaged $40.0 million across 5 years, with a median of $58.5 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) jumped 1883.42% — and 2025, when it grew 1.83%.
• Apogee Therapeutics' Shares Outstanding (Entity) stood at $2.5 million in 2022, then surged by 915.57% to $25.0 million in 2023, then surged by 137.86% to $59.5 million in 2024, then gained by 16.07% to $69.0 million in 2025, then grew by 9.1% to $75.3 million in 2026.
• Business Quant data shows APGE's Shares Outstanding (Entity) at $75.3 million in Q1 2026, $69.0 million in Q4 2025, and $60.1 million in Q3 2025.